Overexpression of cyclooxygenase-2 in non-small cell lung cancer  by Petkova, D.K. et al.
Overexpression of cyclooxygenase-2 in non-small
cell lung cancer
D.K. Petkovaa, C. Clellandb, J. Ronanb, L. Panga, J.M. Coulsonc,
S. Lewisa, A.J. Knoxa,*
aDivision of Respiratory Medicine, City Hospital, University of Nottingham, Hucknall Road,
Nottingham NG5 1PB, UK
bDepartment of Histopathology, City Hospital, University of Nottingham, Nottingham NG5 1PB, UK
cDepartment of Oncology, City Hospital, University of Nottingham, Nottingham NG5 1PB, UK
Received 13 November 2002
Summary Evidence is accumulating to suggest that the inducible isoenzyme of
cyclooxygenase (COX)-2 is up-regulated in human cancers and epidemiological studies
indicate that COX inhibitors may have a protective effect on the development of lung
cancer. We used immunohistochemistry and Western blotting to investigate COX
expression in lung tumour specimens and three lung cancer cell lines. Sixty-five
archival lung tissue samples, including 46 squamous cell and 6 adenocarcinoma lung
resections, and 13 small cell lung cancer (SCLC) biopsies were studied. Dense and
intense cytoplasmic COX-2 staining was found in all 52 resections from non-small cell
lung cancer (NSCLC). The staining was diffuse and much stronger than adjacent
respiratory epithelium. COX-2 staining was relatively weak in the majority of the
SCLC samples. The bronchial and bronchiolar epithelium in the surrounding normal
lung structures showed uniform COX immunoreactivity with apical concentration of
the stain. There was no increase in COX-1 staining in any tumour type. Western blot
analysis of the cancer lines revealed significantly higher expression of COX-1 in
CORL23 line and COX-2 in two NSCLC cell lines (MOR/P; A549) compared with the
expression of COX-1 and COX-2 in cultured normal bronchial epithelial cells. Our
findings demonstrated COX-2 overexpression in NSCLC.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
The burden of lung cancer to society is enormous.
This is one of the leading causes of cancer-related
death worldwide and is associated with almost one
quarter of all cancer deaths, overtaking breast,
prostate, and colon cancer. Lung cancer is highly
resistant to conventional cancer therapy and
although survival rates have improved slightly in
recent years more than 90% of patients diagnosed
with lung cancer die from their disease.1,2 There-
fore, the identification of the mechanisms prevent-
ing or controlling the development and progression
of this deadly disease is urgently required and will
lead to more effective lung cancer management
strategies.
Recent research has shown that both human and
experimental tumours contain increased amounts
of prostaglandin (PG) E2 which modulates cytokine
balance, inhibits host immunity and may play
an important role in carcinogenesis.3,4 PGE2 is
produced from endogenous arachidonic acid by
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cyclooxygenase (COX). Two COX genes have been
identified, COX-1 and COX-2.5 The inducible iso-
form COX-2 has been found to be up-regulated in a
variety of different tumours, including those of the
gastrointestinal tract, lung, head and neck,
breast.6–13 This reflects the increasing interest in
the arachidonic acid cascade and particularly COX-
2 as potential targets for cancer prevention.
COX non-selective and selective inhibitors have
been shown to have anti-neoplastic and prophylac-
tic efficacy against human cancer and in mouse
models of this disease.3,14–32 Epidemiological stu-
dies indicate that the use of aspirin and non-
steroidal anti-inflammatory drugs (NSAIDs) reduces
the incidence of morbidity and mortality from
gastrointestinal, lung and breast cancers.14–22
Sulindac has been shown to decrease the size and
number of the colorectal adenomas in patients with
familial adenomatous polyposis (FAP).23 Several
experimental studies have also demonstrated that
the administration NSAIDs suppresses the tumour-
igenesis in animal models and cancer cell lines.24–30
Tsubouchi et al.31 used the MTT assay and PGE2
enzyme immunoassay to determine that meloxicam
inhibits the growth and PGE2 production of both
A549 and PC14 cancer cell lines. Celecoxib, a
selective COX-2 inhibitor and a potent anti-angio-
genic agent, has been reported to inhibit the
growth of lung and colonic tumours implanted into
recipient mice.32
The majority of the previous studies have
concentrated on human colorectal tumours, lung
adenocarcinomas and other gastrointestinal can-
cers. The published so far data regarding the
expression of COX isoforms in squamous cell lung
cancer remain controversial. Several studies have
shown that COX-2 is also up-regulated in squamous
cell lung cancer compared with normal lung
tissue.10,12,33,34 Watkins et al.,35 however, demon-
strated low or absent expression of COX-2 in 9 out
of 13 squamous cell lung cancer specimens. This
was followed by a larger study conducted by
Hasturk36 revealing that only 15 of the evaluated
samples (9 out of 46) expressed increased levels of
COX-2. In this study, we examined the expression
levels of COX-1 and COX-2 in primary non-small cell
lung cancers (NSCLC) and small cell lung cancer
(SCLC) and showed a significant increase in COX-2
expression not only in lung adenocarcinomas but
also in squamous cell lung tumours. Here we
evaluated the COX-1 and COX-2 immunoreactivity
in a large number of squamous cell lung cancer
patients and report COX-2 overexpression in this
type of NSCLC. In addition we assessed the COX-1
and COX-2 levels in three cultured cancer cell lines
and compared them with these in normal bronchial
epithelial cells. The results demonstrated up-
regulated COX-2 in the NSCLC adenocarcinoma
but not large cell lung cancer cell lines.
Methods
Study population
Non-small lung cancer patients
Lung resection specimens were obtained retro-
spectively from 46 patients with squamous cell
carcinoma [median age 68, range 47–76 years; 37
males] and 6 patients with adenocarcinoma [med-
ian age 69, range 53–71 years; 2 male]. Forty-eight
(92.3%) were smokers or ex-smokers. All patients
had been initially assessed as operable and had
undergone pulmonary resection. No patients had
other treatment for their lung cancer including
chemo- or radiotherapy prior to the surgical interven-
tion. Three patients were on a regular anti-hyperten-
sive treatment and 6 were on inhaled bronchodilators
as required. Samples from tumour nodules were
examined and compared with the surrounding
histologically normal areas of lung parenchyma.
Small cell lung cancer patients
Bronchial biopsies were obtained retrospectively
from 13 patients [median age 66, range 48–81
years, 11 males]. Ten (76.9%) were smokers or ex-
smokers. Two patients were taking anti-hyperten-
sive and three were on inhaled bronchodilators
intermittently. Three patients had a limited and 10
extensive disease.
No patient included in the study had been on
regular medication with aspirin or NSAIDs according
to the medical records.
Tissue specimens and immunohistochemistry
Sixty-five archival lung tissue samples, including 46
squamous cell, 6 adenocarcinoma lung resections,
and 13 SCLC biopsies were studied. Paraffin
embedded tissue blocks were sectioned at 2–3 mm
thickness and mounted on APES coated slides. The
specimens were deparaffinized in fresh xylene and
rehydrated by immersion in graded series of dilute
solutions of ethanol. The tissue sections were then
microwaved in a large vessel containing 1 l of 10mM
citrate buffer (2.1 g citric acid monohydrate and 1 g
NaOH in 1 l de-ionized water, pH 6) for 10min at full
power followed by 10min at 50% power in a 800W
microwave oven. The slides were rapidly cooled,
removed from the citrate buffer and then washed
in Tris buffered saline prior to immunohistochem-
istry. Slides were immersed first in 0.3% hydrogen
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peroxide/methanol for 10min to block endogenous
peroxidase activity. Normal swine serum 15 dilution
in Tris buffered saline was used as a blocking agent
to reduce background staining and to dilute the
primary and secondary antibodies. Immunostaining
was performed using Streptavidin biotin complex/
horse-radish peroxidase immunodetection system
at room temperature. All slides were sequentially
incubated with monoclonal mouse COX-1 or COX-2
antibodies at the dilution 150 for 1 h, biotinylated
goat secondary antibody for 30min and avidin-
biotin peroxidase (ABC) complex solution (ABC
Quick kit protocol) for 1 h. Immunostaining was
visualised with 3,30-diaminobenzidine (DAB) solu-
tion (5mg DAB and 100 ml 3% hydrogen peroxide in
10ml pH 7.6 Tris buffer) for 10min. Sections were
then treated with 0.8% copper sulphate in 0.8%
sodium chloride for 10min, counter-stained in
haematoxylin, dehydrated, cleared in xylene sub-
stitute and mounted in XAM. Negative controls with
the primary antibody absent, or replaced with an
unrelated isotype-matched mouse IgG were in-
cluded. These controls always showed no colour
development. We have previously demonstrated
the specificity of these antibodies for COX-1 and
COX-2 using both Western blotting and immuno-
cytochemistry.37–39
Cell cultures
Normal human bronchial epithelial cells (NHBEC)
Normal human bronchial epithelial cells (NHBEC
4653) obtained from Biowhittaker (Walkersville,
MD, USA) were cultured as previously
described.37,40
A549 (lung adenocarcinoma)
A549 cell line was purchased from the European
Culture Collection. The cells were cultured accord-
ing to a method we have previously described.38,41
Frozen and stored cells were thawed at 371C,
washed twice with PBS, seeded in 24 well tissue
culture plates and incubated in humidified 5% CO2/
95% air at 371C. The culture medium containing
Dulbecco’s modified Eagle’s medium (DMEM) with
10% foetal calf serum (FCS), penicillin G
(100 mml1), streptomycin (100 mgml1), ampho-
tericin B (2.5 mgml1) and L-glutamine (4mM) was
changed every 2 days. Once confluent the cells
were growth arrested in serum-free media for 24 h.
MOR/P (lung adenocarcinoma)
MOR/P cell line was a generous gift from Dr. P.
Twentyman (Cambridge, UK). The P indicates that
these are parental cell lines and not drug resistant
derivatives of these lines.42 Frozen cells were
thawed at 371C, diluted gradually and cultured in
pre-warmed tissue culture media RPMI supplemen-
ted with 10% FBS, penicillin G (100 mml1), strep-
tomycin (100 mgml1), and L-glutamine (2mM).
Initially the cells were seeded into flasks T175
(50ml). The media was changed every 1–2 days.
When confluent the media was aspirated, the cells
washed in PBS and trypsinised in 1–2.5ml of
trypsin/EDTA for 2–5min at room temperature
followed by 5min at 371C. The cells were then re-
suspended in 10ml media and seeded into new
flasks, or stored frozen in freezing mixture
(5%DMSO in BCS) as 1ml aliquots in cryovials. For
the experiments the trysinised cells were re-suspen-
ded in PBS, and grown in 24-well culture plates.
COR-L23/P (large cell lung carcinoma)
COR-L23, P (parental) cell line was also a generous
gift from Dr. P. Twentyman (Cambridge, UK). The
cells are derived from a large cell anaplastic
tumour. They were grown using identical conditions
to MOR/P cell line.
Western blot
COX-1 and COX-2 protein levels in normal human
bronchial epithelial cells were compared with the
levels in the NSCLC lines A549, COR-L23 and MOR/P.
To determine the basal COX isoform distribution in
these cell lines we carried out Western blotting
analysis as previously described. Protein aliquots of
30 mg of the samples were used.38,41 We used the
same antibodies as for the immunohistochemistry.
Scoring of sections
The whole sections were examined. They were
coded and scored semi-quantitatively. The extent
and intensity of the expression of COX isoenzymes
(brown cytoplasmic staining) were assessed as
follows: 0¼ none; 1¼weak and patchy; 2¼weak
but extensive or strong but patchy, and 3¼ strong
and extensive.
Materials
Monoclonal mouse anti-ovine COX-1 with cross-
reactivity to human (Cat N 160110) and monoclonal
mouse anti-human COX-2 (Cat N 160112) antibodies
were purchased from Alexis Corporation (Bingham,
Nottingham, UK, normal swine serum from Sera-lab
(Belton, Loughborough, UK), Vectastain, DAB kit
from Vector Laboratories (Bretton, Peterborough,
UK). Mayer’s hematoxylin, DMEM, penicillin,
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streptomycin, L-glutamine, amphotericin-B were
all purchased from Sigma from Sigma (Poole,
Dorset, UK), and xylene substitute mountant was
purchased from Shandon (Astmoor Runcorn, Che-
shire, UK). The A549 cell line was purchased from
the European Culture Collection. COR-L23 and
MOR/P cell lines were a generous gift from Dr. P.
Twentyman (Cambridge, UK). The NHBE 4653 cells,
Bronchial Epithelial Cell Growth Medium Bullet kit
(BEGM Bullet kit) or Small Airway Epithelial Cell
Growth Medium Bullet kit (SAGM Bullet kit), and
Reagent Pack were obtained from Bio Whittaker
(Walkersville, MD, USA).
Statistical analysis
Statistical analysis was performed using the statis-
tical software SPSS. Differences in staining be-
tween NSCLC and SCLC sections, and the adjacent
normal lung tissue were compared using the
Wilcoxon signed rank and Mann–Whitney U tests.
w2 test, Fishers exact test, or w2 test for trend was
employed to assess the relationship between the
clinicopathological characteristics and the expres-
sion of Cox-2 (recategorised as 1 or 2 vs. 3 because
of small numbers). A P value lower than 0.05 was
regarded as statistically significant. Results are
given as the median (inter-quartile range). The
results were evaluated twice and the intra-obser-
ver variability was assessed utilising kappa analysis.
Results
Immunohistochemistry
The results are summarised in Table 1 and Figs. 1
and 2. The differences in COX-1 and COX-2
expression among the normal lung structures,
NSCLC and SCLC sections were assessed qualita-
tively and semi-quantitatively. The sections were
re-scored twice and the intra-observer variability
was assessed as 10 discrepancies out of 90
observations [kappa agreement 0.796 (SEM 0.06)].
The original value was used in the statistical
analysis.
Dense and intense granular cytoplasmic COX-2
staining was found in all 52 resections from NSCLC
(Fig. 2a). Although COX-2 was most consistently
expressed in the adenocarcinoma sections than in
squamous cell lung cancers the difference did not
reach significance when they were scored sepa-
rately. The staining was diffuse and much stronger
than adjacent respiratory epithelium. Poorly dif-
ferentiated carcinomas seemed to be more strongly
stained for COX-2 when compared with well-
differentiated areas. COX-2 staining was signifi-
cantly lower in the majority of the SCLC samples
[COX-2 score 3 (3, 3) vs. 2 (1, 2.5); NSCLC vs. SCLC;
Po0:001], although some samples still showed
moderate or strong staining (Fig. 2b).
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Table 1 COX immunoreactivity.
NSCLC N1 SCLC N2 P
n ¼ 52 n ¼ 52 n ¼ 13 n ¼ 13 NSCLC/Nn SCLC/Nn NSCLC/SCLCw
COX-1 2 (0, 2) 1 (1, 2) 1 (0, 1) 1 (1, 1) P ¼ 0:482 P ¼ 0:776 P ¼ 0:075
COX-2 3 (3, 3) 1 (1, 1) 2 (1, 2.5) 1 (1, 1.5) Po0:001 P ¼ 0:089 Po0:001
P values for different comparisons are shown. The values are given as the median (inter-quartile range).
NSCLCFnon-small cell lung cancer; SCLCFsmall cell lung cancer; N1Fnormal lung tissue adjacent to NSCLC; N2Fnormal lung
tissue adjacent to SCLC; COXFcyclooxygenase.
nWilcoxon test.
wMann–Whitney U non-parametric test.
COX-2 expression in NSCLC vs. SCLC
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Figure 1 COX-2 expression in NSCLC vs. SCLC.
NSCLCFnon-small cell lung cancer; SCLCFsmall cell
lung cancer; COXFcyclooxygenase; (1) weak and patchy
staining; (2) weak but extensive or strong but patchy
staining and (3) strong and extensive staining.
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There was no increase in COX-1 staining in any
tumour type compared with the normal surrounding
lung tissue, but moderate cytoplasmic staining was
commonly seen (Fig. 2c). Some very large bizarre
tumour cells were stained strongly with both COX-1
and COX-2.
Relationship between COX-2 expression and
clinicopathological characteristics
No significant association was found between COX-2
expression and various clinicopathological para-
meters including age (P ¼ 0:52; P ¼ 0:13 for NSCLC
& SCLC, respectively), sex, smoking and pack-year
smoking history, and the stage of the disease in
both NSCLC and SCLC specimens (Table 2). There
was a significant correlation between the expres-
sion of COX-2 and tumour differentiation in NSCLC.
We determined no significant relationship between
the survival of patients with NSCLC and SCLC and
the level of COX-2 immunoreactivity (P ¼ 0:317;
P ¼ 0:488; respectively).
A similar relationship between the COX-2 levels
and the clinical characteristics of the patients with
squamous cell and adenocarcinomas to those
calculated for NSCLC patients as a whole was found
when the data were reanalysed separately.
COX expression in cancer cell lines
Westerns blot analysis of the three cancer cell lines
revealed significantly higher COX-1 expression in
COR-L23 line and COX-2 expression in two NSCLC
cell lines (MOR/P and A549) in comparison with
COX-1 and COX-2 expression in cultured normal
bronchial epithelial cells, respectively (Fig. 3).
Discussion
Our study demonstrated that COX-2 is overex-
pressed in NSCLC and two cancer cell lines. All 52
NSCLC resections including 46 squamous cell and
6 adenocarcinomas showed intense cytoplasmic
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Figure 2 (a) Strong COX-2 staining of a squamous carcinoma with accentuated staining of the tumour cells sloughing
off into the central necrotic area (top left). Magnification  200. (b) Moderate COX-2 staining of a small cell carcinoma.
Magnification  200. (c) Moderate COX-1 staining of an adenocarcinoma. Magnification  500.
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COX-2 staining, significantly higher compared to
normal lung tissue. This is one of the first studies to
include a large number of squamous cell lung
cancer specimens. By contrast, there was no
significant difference in COX-2 immunoreactivity
in the SCLC sections compared with the normal
surrounding lung tissue. COX-1 showed weak and
patchy cytoplasmic expression in the majority of
the examined lung cancer specimens, as well as in
the normal adjacent lung tissue. Cultured human
NSCLC adenocarcinoma cell lines showed elevated
levels of COX-2 but not COX-1 when compared to
NHBEC.
Our findings are similar to previously published
observations which have used immunohistochem-
ical analysis and molecular biological methods, and
reported overexpression of COX-2 protein in non-
small cell lung cancer, particularly adenocarcino-
mas.13,33–35,43,44 Subsequent research has looked at
the COX immunoreactivity in squamous cell lung
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Table 2 Relationship between COX-2 expression and the patients’ clinico-pathological characteristics.
Patients’
characteristics
NSCLC SCLC
N (%) with
characteristics
N (%) scored 3
for expression
of COX-2
N (%) with
characteristics
N (%) scored 3
for expression
of COX-2
Sex P ¼ 0:14n P ¼ 1w
M 39 (75%) 34 (87%) 11 (85%) 3 (27%)
F 13 (25%) 9 (69%) 2 (15%) 0
Smoking P ¼ 0:08w P ¼ 0:1w
Never 3 (6%) 1 (33%) 2 (17%) 0
Ever 48 (94%) 41 (85%) 10 (83%) 2 (20%)
Pack-years P ¼ 0:24w P ¼ 1w
o40 24 (51%) 22 (92%) 6 (60%) 1 (17%)
440 23 (49%) 18 (78%) 4 (40%) 1 (25%)
Stage P ¼ 0:62z P ¼ 0:52w
NSCLC SCLC
I 9 (18%) 7 (78%)
II Limited 21 (42%) 18 (86%) 3 (23%) 0
IIIA 14 (26%) 12 (85%)
IIIB 4 (8%) 3 (75%)
IV Extensive 3 (6%) 3 (100%) 10 (77%) 3 (30%)
Differentiation P ¼ 0:03z
Well 5 (10%) 2 (40%)
Moderate 23 (46%) 20 (87%)
Poor 22 (44%) 20 (91%)
NSCLCFnon-small cell lung cancer; SCLCFsmall cell lung cancer; COXFcyclooxygenase.
nw2 test.
wFisher’s exact test.
zw2 test for trend.
COR-L23 MOR/P A549 NHBE
COX-1 
COX-2 
Figure 3 Western blot analysis revealed significantly higher COX-1 expression in COR-L23 line and COX-2 expression in
two NSCLC cell lines (MOR/P and A549) compared with COX-1 and COX-2 expression in cultured normal bronchial
epithelial cells, respectively. COXFcyclooxygenase; COR-L23Flarge cell lung carcinoma cell line; MOR/PFlung
adenocarcinoma cell line; A549Flung adenocarcinoma cell line; NHBEFnormal human bronchial epithelial cells.
Cyclooxygenase-2 expression in lung cancer 169
cancer and suggested that COX-2 protein has
similar pattern in both types of NSCLC specimens,
which was also the case in our study.10,12,33,34
Watkins et al.,35 however, found that the most
intense expression of COX-2 mRNA was in lung
adenocarcinoma cells, followed by that in large cell
tumours and the lowest levels were observed in
squamous cell carcinomas. A recently published
immunohistochemical study including 101 NSCLC
resections (51 adenocarcinoma and 46 squamaous
cell lung cancers) showed increased COX-2 levels in
a small proportion 9 of 46 (20%) of the examined
squamous cell lung carcinomas. Also a relatively
small number of the examined adenocarcinomas 21
of 51 (41%) were assessed as COX-2 positive.36 Wolff
et al.12 using two methods Northern blot analysis
and immunohistochemistry demonstrated elevated
COX-2 not only in adenocarcinoma but also in all
examined (11 out of 11) squamous cell lung
carcinoma specimens. Up-regulation of COX-2 has
been observed in squamous cell carcinomas of head
and neck, skin, oesophagus, cervical and urinary
bladder cancers as well.8,9,45,46 The discrepancies
in the reported findings may reflect the different
methods used in these studies and particularly the
different antibodies and their concentration. The
studies, however, in which two different methods
for evaluating COX expression were utilised, have
detected COX-2 overexpression in different squa-
mous cell carcinomas.9,12,45–48
Experiments in animal lung tumourigenesis de-
monstrating increased COX-2 protein levels and
PGE synthesis also support our results. By RT-PCR,
COX-2 PCR products were detected in mouse lung
adenomas.15,16 Bauer showed not only elevated
COX-2 but also COX-1 in mouse lung carcinomas.49
Lewis lung carcinoma cells produce increased
amounts of PGE2, which are blocked by non-
selective COX inhibitors. This leads to reduction
of the growth and metastatic potential of the
tumour cells and indicates that PGE2 may play a
role in the survival and proliferation rate of lung
cancer cells.50
Although our results suggested that COX-2 was
most consistently expressed in the adenocarcinoma
than in squamous cell lung cancer sections, the
difference did not reach significance. The strongest
staining in our study, however, was observed in
poorly differentiated carcinomas. Similar results
were observed by other researchers who reported
greater expression of COX-2 in poorly differen-
tiated lesions than in well or moderately differ-
entiated areas.34,43 Poorly differentiated
adenocarcinomas have been associated with in-
creased metastatic potential and more adverse
prognosis compared to well or moderately differ-
entiated adenocarcinomas.43,44 Wolff’s study,12
however, has described particularly elevated COX-
2 levels in well differentiated adenocarcinomas.
The difference among studies suggests that
further research including a larger number of
tumours is required to clarify this area, which
may have a crucial role for the progression of
the tumour.
We found no significant relationship between the
level of COX-2 expression and the majority of the
clinicopathological characteristics of the patients.
No other studies have previously reported a
significant relationship between COX-2 expression
and most of the clinicopathological characteristics
of the patients. Khuri et al. have demonstrated a
significant correlation between the high level of
COX-2 expression and a worse overall survival rate
(P ¼ 0:001) and a worse disease-free survival rate
(P ¼ 0:022).4
All in vivo studies including ours have shown no
difference between COX-1 expression in NSCLC
sections and the surrounding normal lung tissue.
Similar data have been reported for the COX-1 and
COX-2 immunoreactivity in SCLC.12,36
The findings of our immunohistochemical study
are supported by additional in vitro experiments.
We used Western blot analysis to compare the COX-
1 and COX-2 expression in NHBEC with this in
cultured cancer cell lines. The levels of COX-2 in
both adenocarcinoma cell lines A549 and MOR/P
were higher than these in NHBEC. Tsubouchi also
detected increased COX-2 in the NSCLC cell lines
A549 and PC14 whose growth and PGE2 production
was completely blocked by Meloxicam.31 In con-
trast, COR-L23 cell line showed overexpression of
COX-1 when compared with the NHBEC. Cornetta
et al. studied the COX levels in thyroid neoplasms
and observed no COX-2 expression in anaplastic
carcinomas.51 In a study of mouse lung carcinogen-
esis, both COX-1 and COX-2 were found to be up-
regulated, and different expression patterns were
observed in tumours with different growth pat-
terns.48 In addition, treatment with a tobacco
carcinogen led to induced nuclear factor kappa B
(NFkB) and COX-1 expression in a human macro-
phage model.51 We could speculate that COX-1
expression may also be induced in some types of
lung cancer, perhaps by specific carcinogens. Our
study included no clinical large cell anaplastic lung
cancers and only one study to date has included this
tumour type and found lower COX-2 levels in large
cell than adenocarcinoma.35 This finding may
warrant further investigation, but is beyond the
scope of the current paper.
In conclusion, our data indicate that NSCLC, but
not SCLC, have the ability to express increased
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levels of the inducible COX-2. Further investiga-
tions are required to determine whether modulat-
ing the expression of COX-2 would improve the
prognosis of this deadly disease.
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